Clinical Trial Results: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating sitravatinib with or without other anticancer therapies in advanced or metastatic solid malignancies has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Malignancies

Drugs mentioned

• Sitravatinib (sitravatinib)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced or Metastatic Solid Malignancies | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-08-04